RGEN vs. EXEL, HALO, NBIX, ADPT, BIIB, QGEN, PCVX, RVMD, TECH, and IBRX
Should you be buying Repligen stock or one of its competitors? The main competitors of Repligen include Exelixis (EXEL), Halozyme Therapeutics (HALO), Neurocrine Biosciences (NBIX), Adaptive Biotechnologies (ADPT), Biogen (BIIB), Qiagen (QGEN), Vaxcyte (PCVX), Revolution Medicines (RVMD), Bio-Techne (TECH), and ImmunityBio (IBRX). These companies are all part of the "biological products, except diagnostic" industry.
Repligen (NASDAQ:RGEN) and Exelixis (NASDAQ:EXEL) are both mid-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, profitability, community ranking, dividends, risk and analyst recommendations.
Exelixis has a net margin of 11.10% compared to Repligen's net margin of 2.44%. Exelixis' return on equity of 8.85% beat Repligen's return on equity.
97.6% of Repligen shares are owned by institutional investors. Comparatively, 85.3% of Exelixis shares are owned by institutional investors. 1.2% of Repligen shares are owned by insiders. Comparatively, 2.9% of Exelixis shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Exelixis has higher revenue and earnings than Repligen. Exelixis is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.
Repligen currently has a consensus price target of $197.75, indicating a potential upside of 15.01%. Exelixis has a consensus price target of $26.13, indicating a potential upside of 24.94%. Given Exelixis' higher probable upside, analysts plainly believe Exelixis is more favorable than Repligen.
Exelixis received 176 more outperform votes than Repligen when rated by MarketBeat users. Likewise, 68.12% of users gave Exelixis an outperform vote while only 68.08% of users gave Repligen an outperform vote.
In the previous week, Exelixis had 8 more articles in the media than Repligen. MarketBeat recorded 12 mentions for Exelixis and 4 mentions for Repligen. Repligen's average media sentiment score of 1.24 beat Exelixis' score of 0.76 indicating that Repligen is being referred to more favorably in the media.
Repligen has a beta of 1.03, indicating that its stock price is 3% more volatile than the S&P 500. Comparatively, Exelixis has a beta of 0.57, indicating that its stock price is 43% less volatile than the S&P 500.
Summary
Exelixis beats Repligen on 12 of the 18 factors compared between the two stocks.
Get Repligen News Delivered to You Automatically
Sign up to receive the latest news and ratings for RGEN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Repligen Competitors List
Related Companies and Tools
